This module uses fundamental data of PAVmed Series to approximate its Piotroski F score. PAVmed Series F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of PAVmed Series Z. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about PAVmed Series financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out PAVmed Series Altman Z Score, PAVmed Series Correlation, PAVmed Series Valuation, as well as analyze PAVmed Series Alpha and Beta and PAVmed Series Hype Analysis.
PAVmed
Piotroski F Score
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Total Cashflows From Investing Activities
Depreciation
Investments
Dividends Paid
Issuance Of Capital Stock
Change To Account Receivables
Other Cashflows From Investing Activities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Cash
Cash And Short Term Investments
Common Stock Total Equity
Liabilities And Stockholders Equity
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Common Stock
Accounts Payable
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Common Stock Shares Outstanding
Non Current Liabilities Total
Property Plant And Equipment Net
Property Plant And Equipment Gross
Property Plant Equipment
Short Long Term Debt Total
Net Invested Capital
Accumulated Other Comprehensive Income
Net Working Capital
Short Long Term Debt
Capital Stock
Short Term Debt
Short Term Investments
Net Receivables
Inventory
Capital Lease Obligations
Intangible Assets
Interest Expense
Selling General Administrative
Operating Income
Income Before Tax
Net Income Applicable To Common Shares
Other Operating Expenses
Ebit
Research Development
Ebitda
Total Operating Expenses
Depreciation And Amortization
Total Other Income Expense Net
Net Interest Income
Interest Income
Total Revenue
Gross Profit
Net Income From Continuing Ops
Reconciled Depreciation
Income Tax Expense
Minority Interest
Cost Of Revenue
Selling And Marketing Expenses
Probability Of Bankruptcy
At this time, PAVmed Series' Net Debt is fairly stable compared to the past year. Short and Long Term Debt Total is likely to rise to about 58.8 M in 2025, whereas Long Term Debt is likely to drop slightly above 256.5 K in 2025. At this time, PAVmed Series' Inventory Turnover is fairly stable compared to the past year. Payables Turnover is likely to rise to 3.40 in 2025, whereas Price To Sales Ratio is likely to drop 13.27 in 2025.
At this time, it appears that PAVmed Series' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to PAVmed Series is to make sure PAVmed is not a subject of accounting manipulations and runs a healthy internal audit department. So, if PAVmed Series' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if PAVmed Series' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between PAVmed Series' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards PAVmed Series in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(2.84)
At this time, PAVmed Series' Book Value Per Share is fairly stable compared to the past year.
About PAVmed Series Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PAVmed Series Z's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PAVmed Series using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PAVmed Series Z based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.